Clinical trial · Interventional
Superficial Cervical Plexus Block With Dexmedetomidine Versus Without Adjuvant in Thyroid Surgery
A Randomized Double-Blind Controlled Trial on the Effectiveness of Superficial Cervical Plexus Block With Dexmedetomidine Compared to Without Adjuvant in Thyroid Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Efficacy of Superficial Cervical Plexus Block (SCPB) with Dexmedetomidine Adjuvant Compared to Without Adjuvant in Thyroid Surgery. This is a double-blinded, randomized controlled trial designed to evaluate the effectiveness of adding perineural dexmedetomidine to a Superficial Cervical Plexus Block (SCPB) for pain management in patients undergoing thyroid surgery. The study aims to prove that SCPB with dexmedetomidine adjuvant provides superior post-operative analgesia, lowers total opioid consumption, prolongs the time until the first analgesic request, and reduces the incidence of chronic pain three months post-surgery compared to SCPB without the adjuvant. The study will also evaluate the anti-inflammatory effect by measuring the reduction in Interleukin-6 (IL-6) levels post-operatively and compare the incidence of bradycardia as a side effect. The total required sample size is 58 subjects.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Goiter | — | UNRESOLVED | — |
| Hyperthyroidism | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacain | Drug | — | UNRESOLVED |
| Dexmedetomidine & Bupivacaine. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- SCPB with Dexmedetomidine Adjuvant
- description
- Patients receive Superficial Cervical Plexus Block (SCPB) with Bupivacaine 0.375% and Dexmedetomidine 0.5 mcg/kgbw
- interventionNames
- Drug: Dexmedetomidine & Bupivacaine.
- type
- ACTIVE_COMPARATOR
- label
- SCPB with Placebo/No Adjuvant
- description
- Patients receive Superficial Cervical Plexus Block (SCPB) with Bupivacaine 0.375% only (without Dexmedetomidine adjuvant).
- interventionNames
- Drug: Bupivacain
Primary outcomes (1)
- measure
- Time to First Request for Opioid Analgesia (PCA Button Press)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 59 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 30-59 years. * Patients with ASA physical status classification I-III. * Patients with Body Mass Index (BMI) between 18 and 25 kg/m Exclusion Criteria: * Patients with contraindications for regional anesthesia. * Patients with a history of autoimmune disease. * Presence of infection in the puncture area. * Patients with allergies and contraindications to the use of dexmedetomidine. * Patients on routine medication, including beta-blockers, anti-depressants, or anti-seizure medications. * Prolonged opioid use. * Patients unable to be assessed using the Visual Analogue Scale (VAS) or unable to operate the Patient-Controlled Analgesia (PCA) device. * Patients who refuse to participate in the study.
References
Publications (0)
Data not yet available